Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS

Authors: Rodriguez-Otero, Paula ^{1, ⁎}, Voorhees, Peter M. ², Boccadoro, Mario ³, Laubach, Jacob ⁴, Einsele, Hermann ⁵, Sborov, Douglas W. ⁶, Dimopoulos, Meletios A. ⁷, Broijl, Annemiek ⁸, Mina, Roberto ⁹, Spencer, Andrew ¹⁰, Schjesvold, Fredrik ¹¹, Silbermann, Rebecca ¹², Gay, Francesca ⁹, Costa, Luciano J. ¹³, Perrot, Aurore ¹⁴, Liu, Yanfang ¹⁵, Wang, Jianping ¹⁶, Sitthi-Amorn, Anna ¹⁶, Carson, Robin ¹⁶, Cortoos, Annelore ¹⁷, Usmani, Saad Z. ¹⁸, Richardson, Paul G. ⁴, Moreau, Philippe ¹⁹, Sonneveld, Pieter ⁸, Kaufman, Jonathan L. ²⁰

Source: In Clinical Lymphoma, Myeloma and Leukemia April 2025

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Authors: Corre, Jill ^{1, ∗}, Vincent, Laure ², Moreau, Philippe ³, Hebraud, Benjamin ⁴, Hulin, Cyrille ⁵, Béné, Marie-Christine ⁶, Broijl, Annemiek ⁷, Caillot, Denis ⁸, Delforge, Michel ⁹, Dejoie, Thomas ¹⁰, Facon, Thierry ¹¹, Lambert, Jérôme ¹², Leleu, Xavier ¹³, Macro, Margaret ¹⁴, Perrot, Aurore ⁴, Zweegman, Sonja ¹⁵, Filleron, Thomas ¹⁶, Cabarrou, Bastien ¹⁶, van de Donk, Niels W. C. J. ¹⁵, Mahéo, Sabrina ¹, Hua, Winnie ¹⁷, Wang, Jianping ¹⁸, Krevvata, Maria ¹⁸, Vanquickelberghe, Véronique ¹⁹, de Boer, Carla ²⁰, Tuozzo, Alba ¹⁸, Borgsten, Fredrik ²¹, Rowe, Melissa ²², Carson, Robin ¹⁸, Wuilleme, Soraya ⁶, Sonneveld, Pieter ⁷

Source: In Blood March 2025

Changes in income and employment after diagnosis among patients with multiple myeloma in The Netherlands

Authors: Bennink, Christine, Brink, Mirian, Duijts, Saskia F.A., Scheurer, Hans, Sonneveld, Pieter, Blommestein, Hedwig M.

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24(9):604-610

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Authors: Moreau, Philippe ^*, Hulin, Cyrille, Perrot, Aurore, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Zweegman, Sonja, Caillon, Hélène, Caillot, Denis, Avet-Loiseau, Hervé, Delforge, Michel, Dejoie, Thomas, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Mohty, Mohamad, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Orsini-Piocelle, Frédérique, Roussel, Murielle, Schiano de Colella, Jean Marc, van de Donk, Niels WCJ, Wuillème, Soraya, Broijl, Annemiek, Touzeau, Cyrille, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K, Levin, Mark-David, Offner, Fritz, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Réda, Hua, Winnie, Wang, Jianping, Tuozzo, Alba, de Boer, Carla, Rowe, Melissa, Vanquickelberghe, Veronique, Carson, Robin, Vermeulen, Jessica, Corre, Jill, Sonneveld, Pieter

Source: In The Lancet Oncology August 2024 25(8):1003-1014

Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study

Authors: Jaccard, Arnaud, Bridoux, Frank, Roeloffzen, Wilfried, Minnema, Monique C., Bergantim, Rui, Hájek, Roman, João, Cristina, Cibeira, M. Teresa, Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Dimopoulos, Meletios A., Ravichandran, Sriram, Hegenbart, Ute, Agis, Hermine, Gros, Blanca, Asra, Aisha, Magarotto, Valeria, Cheliotis, Giorgos, Psarros, Giorgos, Sonneveld, Pieter, Wechalekar, Ashutosh, Kastritis, Efstathios

Source: In Clinical Lymphoma, Myeloma and Leukemia May 2024 24(5):e205-e216

Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

Authors: Spencer, Andrew, Moreau, Philippe, Mateos, Maria-Victoria, Goldschmidt, Hartmut, Suzuki, Kenshi, Levin, Mark-David, Sonneveld, Pieter, Orlowski, Robert Z., Yoon, Sung-Soo, Usmani, Saad Z., Weisel, Katja, Reece, Donna, Ahmadi, Tahamtan, Pei, Huiling, Mayo, Wendy Garvin, Gai, Xue, Carey, Jodi, Bartlett, J. Blake, Carson, Robin, Dimopoulos, Meletios A.

Source: In Blood Advances 23 January 2024 8(2):388-398

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

Authors: Dimopoulos, Meletios A ^*, Terpos, Evangelos, Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Baldini, Luca, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria-Victoria, Einsele, Hermann, Orfanidis, Ioannis, Kampfenkel, Tobias, Liu, Weiping, Wang, Jianping, Kosh, Michele, Tran, NamPhuong, Carson, Robin, Sonneveld, Pieter

Source: In The Lancet Haematology October 2023 10(10):e813-e824

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

Authors: Groen, Kaz, Stege, Claudia A.M., Nasserinejad, Kazem, de Heer, Koen, van Kampen, Roel J.W., Leys, Rineke B.L., Thielen, Noortje, Westerman, Matthijs, Wu, Ka-Lung, Ludwig, Inge, Issa, Djamila E., Velders, Gerjo A., Vekemans, Marie-Christiane, Timmers, Gert-Jan, de Boer, Fransien, Tick, Lidwine W., Verbrugge, Annelies, Buitenhuis, Danny, Cunha, Sonia M., van der Spek, Ellen, de Waal, Esther G.M., Sohne, Maaike, Sonneveld, Pieter, Nijhof, Inger S., Klein, Saskia K., van de Donk, Niels W.C.J., Levin, Mark-David, Ypma, Paula F., Zweegman, Sonja

Source: In eClinicalMedicine September 2023 63

Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies

Authors: Sonneveld, Pieter, Richardson, Paul G., Ludwig, Heinz, Dimopoulos, Meletios-Athanasios, Schjesvold, Fredrik H., Hájek, Roman, Abdulhaq, Haifaa, Thuresson, Marcus, Norin, Stefan, Bakker, Nicolaas A., Mateos, Maria-Victoria

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23(9):687-696

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma.

Authors: Dimopoulos, Meletios¹ (AUTHOR), Sonneveld, Pieter² (AUTHOR), Manier, Salomon³ (AUTHOR), Lam, Annette⁴ (AUTHOR), Roccia, Tito⁴ (AUTHOR), Schecter, Jordan M.⁵ (AUTHOR), Cost, Patricia⁴ (AUTHOR), Pacaud, Lida⁶ (AUTHOR), Poirier, Abbey⁷ (AUTHOR), Tremblay, Gabriel⁷ (AUTHOR), Lan, Tommy⁷ (AUTHOR), Valluri, Satish⁴ (AUTHOR), Kumar, Shaji⁸ (AUTHOR) kumar.shaji@mayo.edu

Source: BMC Cancer. 4/29/2024, Vol. 24 Issue 1, p1-7. 7p.

Subject Terms: *OVERALL survival, *PROGRESSION-free survival, *MULTIPLE myeloma, *PEARSON correlation (Statistics), *BIBLIOGRAPHIC databases

High hospital-related burden of treatment for multiple myeloma patients: outcomes of a feasibility study using reimbursement data from electronic health records

Authors: Bennink, Christine, van der Klift, Marjolein, Sonneveld, Pieter, Hazelzet, Jan A., Blommestein, Hedwig M.

Source: In Health Policy and Technology December 2022 11(4)

Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials.

Authors: Shi, Qian¹ (AUTHOR) shi.qian2@mayo.edu, Paiva, Bruno² (AUTHOR), Pederson, Levi D.¹ (AUTHOR), Dimier, Natalie³ (AUTHOR), Talpes, Ela⁴ (AUTHOR), Prior, Thomas J.⁵ (AUTHOR), Orfao, Alberto⁶ (AUTHOR), Moreau, Philippe⁷ (AUTHOR), Sonneveld, Pieter⁸ (AUTHOR), Kumar, Shaji K.⁹ (AUTHOR), Dixon, Jesse G.¹ (AUTHOR), Patel, Reshma¹⁰ (AUTHOR), Bartlett, Blake J.⁵ (AUTHOR), Schecter, Jordan⁵ (AUTHOR), McCarthy, Phillip¹¹ (AUTHOR), Hose, Dirk¹² (AUTHOR), Seckinger, Anja¹² (AUTHOR), Mattia, D'Agostino¹³ (AUTHOR), Goldschmidt, Hartmut¹⁴ (AUTHOR), Oliva, Stefania¹⁵ (AUTHOR)

Source: Journal of Clinical Oncology. 4/10/2025, Vol. 43 Issue 11, p1289-1301. 19p.

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

Authors: Thanarajasingam, Gita ^*, Minasian, Lori M, Bhatnagar, Vishal, Cavalli, Franco, De Claro, R Angelo, Dueck, Amylou C, El-Galaly, Tarec C, Everest, Neil, Geissler, Jan, Gisselbrecht, Christian, Gormley, Nicole, Gribben, John, Horowitz, Mary, Ivy, S Percy, Jacobson, Caron A, Keating, Armand, Kluetz, Paul G, Kwong, Yok Lam, Little, Richard F, Matasar, Matthew J, Mateos, Maria-Victoria, McCullough, Kristen, Miller, Robert S, Mohty, Mohamad, Moreau, Philippe, Morton, Lindsay M, Nagai, Sumimasa, Nair, Abhilasha, Nastoupil, Loretta, Robertson, Kaye, Sidana, Surbhi, Smedby, Karin E, Sonneveld, Pieter, Tzogani, Kyriaki, van Leeuwen, Flora E, Velikova, Galina, Villa, Diego, Wingard, John R, Seymour, John F, Habermann, Thomas M

Source: In The Lancet Haematology May 2022 9(5):e374-e384

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Authors: Cavo, Michele ^*, San-Miguel, Jesus, Usmani, Saad Z., Weisel, Katja, Dimopoulos, Meletios A., Avet-Loiseau, Hervé, Paiva, Bruno, Bahlis, Nizar J., Plesner, Torben, Hungria, Vania, Moreau, Philippe, Mateos, Maria-Victoria, Perrot, Aurore, Iida, Shinsuke, Facon, Thierry, Kumar, Shaji, van de Donk, Niels W.C.J., Sonneveld, Pieter, Spencer, Andrew, Krevvata, Maria, Heuck, Christoph, Wang, Jianping, Ukropec, Jon, Kobos, Rachel, Sun, Steven, Qi, Mia, Munshi, Nikhil

Source: In Blood 10 February 2022 139(6):835-844

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Authors: Schjesvold, Fredrik, Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Nikolayeva, Anna, Tomczak, Waldemar, Pour, Ludek, Spicka, Ivan, Dimopoulos, Meletios-Athanasios, Masszi, Tamas, Doronin, Vadim, Minarik, Jiri, Salogub, Galina, Alekseeva, Yulia, Maisnar, Vladimir, Mikala, Gabor, Rosinol, Laura, Konstantinova, Tatiana, Lazzaro, Antonio, Liberati, Anna Marina, Symeonidis, Anargyros, Gatt, Moshe, Illes, Arpad, Abdulhaq, Haifaa, Dungarwalla, Moez, Grosicki, Sebastian, Hajek, Roman, Leleu, Xavier, Myasnikov, Alexander, Richardson, Paul G., Avivi, Irit, Deeren, Dries, Gironella, Mercedes, Hernandez-Garcia, Miguel Teodoro, Martinez Lopez, Joaquin, Newinger-Porte, Muriel, Ribas, Paz, Samoilova, Olga, Voog, Eric, Arnao-Herraiz, Mario, Carrillo-Cruz, Estrella, Corradini, Paolo, Dodlapati, Jyothi, Granell Gorrochategui, Miquel, Huang, Shang-Yi, Jenner, Matthew, Karlin, Lionel, Kim, Jin Seok, Kopacz, Agnieszka, Medvedeva, Nadezhda, Min, Chang-Ki, Mina, Roberto, Palk, Katrin, Shin, Ho-Jin, Sohn, Sang Kyun, Sonneveld, Pieter, Tache, Jason, Anagnostopoulos, Achilles, Arguiñano, Jose-Maria, Cavo, Michele, Filicko, Joanne, Garnes, Margaret, Halka, Janusz, Herzog-Tzarfati, Kathrin, Ipatova, Natalia, Kim, Kihyun, Krauth, Maria-Theresa, Kryuchkova, Irina, Lazaroiu, Mihaela Cornelia, Luppi, Mario, Proydakov, Andrei, Rambaldi, Alessandro, Rudzianskiene, Milda, Yeh, Su-Peng, Alcalá-Peña, Maria Magdalena, Alegre Amor, Adrian, Alizadeh, Hussain, Bendandi, Maurizio, Brearton, Gillian, Brown, Randall, Cavet, Jim, Dally, Najib, Egyed, Miklos, Hernández-Rivas, José Ángel, Kaare, Ain, Karsenti, Jean-Michel, Kloczko, Janusz, Kreisle, William, Lee, Je-Jung, Legiec, Wojciech, Machherndl-Spandl, Sigrid, Manda, Sudhir, Mateos, Maria-Victoria, Moiseev, Ivan, Moreb, Jan, Nagy, Zsolt, Nair, Santosh, Oriol-Rocafiguera, Albert, Osswald, Michael, Otero-Rodriguez, Paula, Peceliunas, Valdas, Plesner, Torben, Rey, Philippe, Rossi, Giuseppe, Stevens, Don, Suriu, Celia, Tarella, Corrado, Verlinden, Anke, Zannetti, Alain, Schjesvold, Fredrik H ^*, Pour, Luděk, Špička, Ivan, Mikala, Gábor, Rosiñol, Laura, Symeonidis, Argiris, Moody, Victoria, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A, Hájek, Roman, Richardson, Paul G

Source: In The Lancet Haematology February 2022 9(2):e98-e110

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

Authors: Frerichs, Kristine A. ¹, Minnema, Monique C. ², Levin, Mark-David ³, Broijl, Annemiek ⁴, Bos, Gerard M.J. ⁵, Kersten, Marie José ⁶, Mutis, Tuna ¹, Verkleij, Christie P.M. ¹, Nijhof, Inger S. ¹, Maas-Bosman, Patricia W.C. ¹, Klein, Saskia K. ^{7, 8}, Zweegman, Sonja ¹, Sonneveld, Pieter ⁴, van de Donk, Niels W.C.J. ^{1, *}

Source: In Blood Advances 14 December 2021 5(23):5128-5139

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Authors: Ludwig, Heinz ^*, Sonneveld, Pieter, Facon, Thierry, San-Miguel, Jesus, Avet-Loiseau, Hervé, Mohty, Mohamad, Mateos, Maria-Victoria, Moreau, Philippe, Cavo, Michele, Pawlyn, Charlotte, Zweegman, Sonja, Engelhardt, Monika, Driessen, Christoph, Cook, Gordon, Dimopoulos, Melitios A, Gay, Francesca, Einsele, Hermann, Delforge, Michel, Caers, Jo, Weisel, Katja, Jackson, Graham, Garderet, Laurent, van de Donk, Niels, Leleu, Xavier, Goldschmidt, Hartmut, Beksac, Meral, Nijhof, Inger, Schreder, Martin, Abildgaard, Niels, Hajek, Roman, Zojer, Niklas, Kastritis, Efstathios, Broijl, Annemiek, Schjesvold, Fredrik, Boccadoro, Mario, Terpos, Evangelos

Source: In The Lancet Haematology December 2021 8(12):e934-e946

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Authors: Moreau, Philippe ^*, Hulin, Cyrille, Perrot, Aurore, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Béné, Marie C, Zweegman, Sonja, Caillon, Hélène, Caillot, Denis, Corre, Jill, Delforge, Michel, Dejoie, Thomas, Doyen, Chantal, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Mohty, Mohamad, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Orsini-Piocelle, Frédérique, Roussel, Murielle, Stoppa, Anne-Marie, van de Donk, Niels W C J, Wuillème, Soraya, Broijl, Annemiek, Touzeau, Cyrille, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K, Levin, Mark-David, Offner, Fritz, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Réda, Ahmadi, Tahamtan, Krevvata, Maria, Zhang, Ke, de Boer, Carla, Vara, Sanjay, Kampfenkel, Tobias, Vanquickelberghe, Veronique, Vermeulen, Jessica, Avet-Loiseau, Hervé, Sonneveld, Pieter

Source: In The Lancet Oncology October 2021 22(10):1378-1390

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Authors: Alegre Amor, Adrian, Baldini, Luca, Beksac, Meral, Belotti, Angelo, Benboubker, Lotfi, Besemer, Britta, Besisik, Sevgi, Bila, Jelena, Boccadoro, Mario, Cavo, Michele, De La Rubia Comos, Javier, Delimpasi, Sosana, Dimopoulos, Meletios A., Doyen, Chantal, Dytfeld, Dominik, Engelhardt, Monika, Facon, Thierry, Foà, Roberto, Goldschmidt, Hartmut, Grosicki, Sebastian, Hajek, Roman, Hayri Ozsan, Guner, Hulin, Cyrille, Iversen, Brian, Karlin, Lionel, Katodritou, Eirini, Knop, Stefan, Kyrtsonis, Marie-Christine, Lahuerta, Juan Jose, Leleu, Xavier, Martinez Chamorro, Carmen, Mateos Manteca, María-Victoria, Meuleman, Nathalie, Minnema, Monique, Moreau, Philippe, Offidani, Massino, Oriol Rocafiguera, Albert, Pehlivan, Mustafa, Pour, Ludek, Roerdink, Henk Th.J., Rosinol Dacsh, Laura, Salwender, Hans, Sonneveld, Pieter, Symeonidis, Anargyros, Toftmann Hansen, Charlotte, Tuglular, Tulin, Unal, Ali, Vlummens, Philip, Vural, Filiz, Wu, Ka Lung, Zweegman, Sonja, Dimopoulos, Meletios A ^*, Terpos, Evangelos, Symeonidis, Argiris, Oriol, Albert, Mateos, Maria-Victoria, Einsele, Hermann, Orfanidis, Ioannis, Ahmadi, Tahamtan, Ukropec, Jon, Kampfenkel, Tobias, Schecter, Jordan M, Qiu, Yanping, Amin, Himal, Vermeulen, Jessica, Carson, Robin

Source: In The Lancet Oncology June 2021 22(6):801-812

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

Authors: Verkleij, Christie P.M., Broekmans, Marloes E.C., van Duin, Mark, Frerichs, Kristine A., Kuiper, Rowan, de Jonge, A. Vera, Kaiser, Martin, Morgan, Gareth, Axel, Amy, Boominathan, Rengasamy, Sendecki, Jocelyn, Wong, Amy, Verona, Raluca I., Sonneveld, Pieter, Zweegman, Sonja, Adams, Homer C., III, Mutis, Tuna, van de Donk, Niels W.C.J. ^*

Source: In Blood Advances 27 April 2021 5(8):2196-2215